HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma

Abstract Immunotherapy has been applied successfully to treat B-cell lymphomas in preclinical models or clinical settings. However, immunotherapy resistance is a major challenge for B-cell lymphoma treatment. To overcome this issue, combinatorial therapeutic strategies have been pursued to achieve a...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Protein & Cell
المؤلفون الرئيسيون:	Xiaoguang Wang, Brittany C. Waschke, Rachel A Woolaver, Samantha M. Y. Chen, Zhangguo Chen, Jing H. Wang
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Oxford University Press 2020-03-01
الموضوعات:	cancer immunotherapy HDAC inhibitor B-cell lymphomas anti-PD1 resistance tumor immunogenicity
الوصول للمادة أونلاين:	https://doi.org/10.1007/s13238-020-00694-x